Nicholas Jacobus is a content associate for Pharmaceutical Executive and can be reached at njacobus@mjhlifesciences.com.
Ovid Therapeutics and Metagenomi unveil leadership changes and financial results, highlighting strategic shifts and future growth opportunities in biotech.
Bristol Myers Squibb and Sarah Cannon Research Institute expanded their strategic collaboration, leveraging SCRI’s Accelero model to streamline operations, embed studies within community care settings, and extend cutting-edge oncology therapies to more diverse patient populations.
Following the removal of George Tidmarsh, HHS and FDA has appointed Richard Pazdur, M.D., director of CDER.
In today’s Pharmaceutical Executive Daily, we report on new data showing Wegovy’s potential to reduce liver injury in patients with MASH, Eli Lilly’s latest strategic collaborations in gene therapy, and Novo Nordisk’s decision not to increase its acquisition offer for Metsera following Pfizer’s entry.
Per the FDA's request, HHS is updating hormone therapy labels, removing misleading warnings to empower women in managing menopause and improving their health options.
In today’s Pharmaceutical Executive Daily, we cover the FDA’s approval of Darzalex Faspro for adults with high-risk smoldering multiple myeloma, the industry’s growing interest in direct-to-patient wholesale models, and the FDA’s expansion of its National Priority Voucher program to accelerate review of critical therapies.
Eli Lilly is partnering with MeiraGTx to develop and commercialize ophthalmology gene therapies, and with SanegeneBio to advance RNAi-based treatments for metabolic diseases, with the agreements collectively valued at more than $1.6 billion in potential milestone payments.
Metsera finalizes a $10 billion merger with Pfizer after rejecting Novo Nordisk's bids amid legal concerns to ensure shareholder value and regulatory safety.
In today’s Pharmaceutical Executive Daily, we cover Eli Lilly and Novo Nordisk’s plans to bring their leading weight-loss medications to the TrumpRx platform, the State of Texas’ legal move to block Kenvue’s dividend payment, and the FDA approval of Darzalex Faspro for adults with high-risk smoldering multiple myeloma.
Johnson & Johnson secures FDA approval for Darzalex Faspro as the first and only treatment for adults with high-risk smoldering multiple myeloma, supported by Phase III Aquila trial data showing a 51% reduction in disease progression or death.
In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s amended proposal to acquire Metsera, the State of Texas’ attempt to block Kenvue’s planned dividend payment, and how data and AI are transforming pharma’s next frontier in commercial customer engagement.
FDA’s approval of Caplyta as an adjunctive treatment to oral antidepressants for major depressive disorder in adults, expands the drug’s use to a fourth indication following positive Phase III trial results.
Raj Indupuri, CEO, eClinical Solutions, touched on how AI can significantly enhance risk identification and mitigation in clinical trials by enabling integrated, data-driven quality management from protocol design onward.
In today’s Pharmaceutical Executive Daily, we cover Kimberly-Clark’s $48.7 billion acquisition of Kenvue, Cencora’s $1 billion investment to strengthen U.S. pharmaceutical distribution, and new industry collaborations advancing autoimmune and oncology research pipelines.
Following Pfizer's lawsuits, Novo Nordisk enhanced its acquisition offer for Metsera, resulting in Pfizer also sending an enhanced offer.
Boehringer Ingelheim and Merck focus on innovative biologic and oncology advancements, driving collaborative growth through new R&D funding, and development and commercialization agreements.
Cencora's investment includes new automated centers in Ohio and California and a major cold chain expansion in Alabama to enhance capacity, efficiency, and supply chain resilience.
Raj Indupuri, CEO, eClinical Solutions,emphasized that robust data strategy and infrastructure are essential for realizing AI’s full potential in pharma.
In today’s Pharmaceutical Executive Daily, we cover Pfizer’s lawsuits against Metsera and Novo Nordisk over alleged intellectual property infringement, Eli Lilly’s $3 billion investment in a new Netherlands manufacturing site, and the latest wave of biotech partnerships and licensing agreements driving innovation.
FDA's approval of Kygevvi as the first treatment for thymidine kinase 2 deficiency offers hope to patients and families affected by this rare disease.
Pharmaceutical collaborations thrive as Manifold Bio, 4DMT, and Kaigene forge strategic partnerships to advance innovative therapies for neurological and autoimmune diseases.
Raj Indupuri, CEO, eClinical Solutions,pharma’s biggest AI adoption hurdles lie in scaling beyond pilots, ensuring data security, and building user trust within a regulated environment.
In today’s Pharmaceutical Executive Daily, we cover Eli Lilly’s plan to submit its oral GLP-1 candidate for FDA priority review, the departure of senior FDA official George Tidmarsh, and growing global venture capital investment in biopharma innovation.
Pfizer's lawsuits come after Novo Nordisk proposed an unsolicited acquisition proposal to Metsera.
Eli Lilly invests $3 billion in a new European manufacturing facility, enhancing production capacity and creating jobs while ensuring faster access to innovative medicines.
Raj Indupuri, CEO, eClinical Solutions, touches on AI's transformation of pharma by streamlining clinical development processes, automating data management, accelerating cycle times, and improving decision-making across trials.
In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s unsolicited proposal to acquire Metsera, renewed legal action against Tylenol’s manufacturer following statements from Robert F. Kennedy Jr., and AbbVie’s stronger 2025 profit outlook driven by immunology demand.
Nine drugs from leading manufacturers will participate in HRSA’s new 340B rebate model pilot program, set to begin in 2026, which aims to evaluate a rebate-based framework for future drug pricing models amid ongoing industry litigation.
The change was driven by strong sales of Skyrizi and Rinvoq, and showcases robust growth and innovation in its portfolio.
In today’s Pharmaceutical Executive Daily, we cover Thermo Fisher’s $8 billion agreement to acquire Clario Holdings, Eli Lilly’s partnership with Walmart to launch retail pickup for its direct-to-consumer Zepbound program, and the FDA’s new draft guidance aimed at streamlining biosimilar development.
